{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:09:02Z","timestamp":1767992942232,"version":"3.49.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nanoadjuvants that combine immunostimulatory properties and delivery systems reportedly bestow major improvements on the efficacy of recombinant, protein-based vaccines. Among these, self-assembled micellar formulations named ISCOMs (immune stimulating complexes) show a great ability to trigger powerful immunological responses against infectious pathogens. Here, a nanoadjuvant preparation, based on saponins from<jats:italic>Quillaja brasiliensis<\/jats:italic>, was evaluated together with an experimental Zika virus (ZIKV) vaccine (IQB80-zEDIII) and compared to an equivalent vaccine with alum as the standard adjuvant. The preparations were administered to mice in two doses (on days zero and 14) and immune responses were evaluated on day 28 post-priming. Serum levels of anti-Zika virus IgG, IgG1, IgG2b, IgG2c, IgG3 were significantly increased by the nanoadjuvant vaccine, compared to the mice that received the alum-adjuvanted vaccine or the unadjuvanted vaccine. In addition, a robust production of neutralizing antibodies and<jats:italic>in vitro<\/jats:italic>splenocyte proliferative responses were observed in mice immunized with IQB80-zEDIII nanoformulated vaccine. Therefore, the IQB80-zEDIII recombinant preparation seems to be a suitable candidate vaccine for ZIKV. Overall, this study identified saponin-based delivery systems as an adequate adjuvant for recombinant ZIKV vaccines and has important implications for recombinant protein-based vaccine formulations against other flaviviruses and possibly enveloped viruses.<\/jats:p>","DOI":"10.3389\/fimmu.2021.632714","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T04:47:57Z","timestamp":1614833277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From Quillaja brasiliensis Enhances Anti-Zika Immune Responses, Including Neutralizing Antibodies and Splenocyte Proliferation"],"prefix":"10.3389","volume":"12","author":[{"given":"Samuel","family":"Cibulski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Muterle","family":"Varela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thais Fumaco","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn Pablo","family":"Cancela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Sesterheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo Onofre","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Michel","family":"Roehe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJMoa1709481","article-title":"Pregnancy outcomes after ZIKV infection in french territories in the Americas","volume":"378","author":"Hoen","year":"2018","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1016\/j.vaccine.2017.04.052","article-title":"Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus","volume":"35","author":"Yang","year":"2017","journal-title":"Vaccine."},{"key":"B5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: from 1920 to 2015 and beyond","volume":"3","author":"Pasquale","year":"2015","journal-title":"Vaccines."},{"key":"B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: a review on adjuvants in licensed vaccines","volume":"39","author":"Del Giudice","year":"2018","journal-title":"Sem Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity."},{"key":"B8","doi-asserted-by":"publisher","first-page":"152905","DOI":"10.1016\/j.phymed.2019.152905","article-title":"Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: a review","volume":"60","author":"Lacaille-Dubois","year":"2019","journal-title":"Phytomedicine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vacc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13323","DOI":"10.1038\/ncomms13324","article-title":"Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation","volume":"7","author":"Den Brok","year":"2016","journal-title":"Nat Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.vaccine.2009.01.091","article-title":"Advances in saponin-based adjuvants","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine."},{"key":"B13","first-page":"311","article-title":"ISCOMATRIX adjuvant in the development of prophylactic therapeutic vaccines","volume-title":"Immunopotentiators In Modern Vaccines.","author":"Morelli","year":"2019"},{"key":"B14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from quillaja saponaria molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4161\/hv.6.3.10754","article-title":"ISCOMATRIX vaccines: safety in human clinical studies","volume":"6","author":"McKenzie","year":"2010","journal-title":"Hum Vacc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.4155\/fmc-2018-0438","article-title":"Foamy matters: an update on Quillaja saponins and their use as immunoadjuvants","volume":"11","author":"Magedans","year":"2019","journal-title":"Fut Med Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.vaccine.2016.01.029","article-title":"Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake","volume":"34","author":"Cibulski","year":"2016","journal-title":"Vaccine."},{"key":"B18","doi-asserted-by":"publisher","first-page":"13582","DOI":"10.1038\/s41598-018-31995-1","article-title":"Quillaja brasiliensis saponin-based nanoparticulate adjuvants are capable of triggering early immune responses","volume":"8","author":"Cibulski","year":"2018","journal-title":"Scient Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature."},{"key":"B21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/v10110615","article-title":"Persistence and intra-host genetic evolution of zika virus infection in symptomatic adults: a special view in the male reproductive system","volume":"10","author":"Oliveira","year":"2018","journal-title":"Viruses."},{"key":"B22","article-title":"Purification of an immunoadjuvant saponin fraction from quillaja brasiliensis leaves by reversed-phase silica gel chromatography","volume-title":"Methods in Molecular Biology","author":"Yendo","year":"2017"},{"key":"B23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1211\/0022357056280","article-title":"Immuno-stimulating complexes prepared by ethanol injection","volume":"57","author":"Lendemans","year":"2005","journal-title":"J Pharm Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.vaccine.2020.12.004","article-title":"IMXQB-80: a Quillaja brasiliensis saponin-based nanoadjuvant enhances Zika virus specific immune responses in mice","volume":"39","author":"Cibulski","year":"2021","journal-title":"Vaccine."},{"key":"B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.vaccine.2017.11.030","article-title":"Leaf saponins of Quillaja brasiliensis enhance long-term specific immune responses and promote dose-sparing effect in BVDV experimental vaccines","volume":"36","author":"Cibulski","year":"2018","journal-title":"Vaccine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cimid.2016.01.004","article-title":"Quillaja brasiliensis saponins induce robust humoral and cellular responses in a bovine viral diarrhea virus vaccine in mice","volume":"45","author":"Cibulski","year":"2016","journal-title":"Comp Immunol Microb Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.pep.2010.05.001","article-title":"Human SUMO fusion systems enhance protein expression and solubility","volume":"73","author":"Wang","year":"2010","journal-title":"Protein Expr Purif."},{"key":"B28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/icb.2011.71","article-title":"ISCOMATRIX vaccines mediate CD8 T-cell cross-priming by a MyD88-dependent signaling pathway","volume":"90","author":"Wilson","year":"2012","journal-title":"Immunology and Cell Biology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/00062752-200101000-00010","article-title":"Germinal center reaction","volume":"8","author":"McHeyzer-Williams","year":"2001","journal-title":"Curr Opin Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1074-7613(00)80533-6","article-title":"Cytokines induce the development of functionally heterogeneous T helper cell subsets","volume":"8","author":"O'Garra","year":"1998","journal-title":"Immunity."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo","volume":"20","author":"Dilillo","year":"2014","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5302","DOI":"10.1016\/j.vaccine.2015.04.099","article-title":"Molecular signatures of vaccine adjuvants","volume":"33","author":"Olafsdottir","year":"2015","journal-title":"Vaccine."},{"key":"B34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1128\/IAI.70.2.584-590.2002","article-title":"Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine","volume":"70","author":"Vermont","year":"2002","journal-title":"Infect Immun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1128\/CVI.00341-13","article-title":"Antibody avidity in humoral immune responses in Bangladeshi children and adults following administration of an oral killed cholera vaccine","volume":"20","author":"Alam","year":"2013","journal-title":"Cli Vacc Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.vaccine.2004.07.014","article-title":"Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response","volume":"23","author":"Siegrist","year":"2004","journal-title":"Vaccine."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/jama.267.11.1489","article-title":"Avidity and bactericidal activity of antibody elicited by different haemophilus influenzae type b conjugate vaccines","volume":"267","author":"Schlesinger","year":"1992","journal-title":"JAMA."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1126\/science.276.5321.2024","article-title":"The role of antibody concentration and avidity in antiviral protection","volume":"276","author":"Bachmann","year":"1997","journal-title":"Science."},{"key":"B39","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1016\/j.vaccine.2020.09.069","article-title":"Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S\/AS01 vaccination","volume":"38","author":"Thompson","year":"2020","journal-title":"Vaccine."},{"key":"B40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/vaccines2020252","article-title":"Adjuvants in the driver's seat: how magnitude, type, fine specificity and longevity of immune responses are driven by distinct classes of immune potentiators","volume":"2","author":"Bergmann-Leitner","year":"2014","journal-title":"Vaccines."},{"key":"B41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.0105-2896.2004.00144.x","article-title":"Modulating vaccine responses with dendritic cells and toll-like receptors","volume":"199","author":"Pulendran","year":"2004","journal-title":"Immunol Rev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"9177","DOI":"10.1016\/j.vaccine.2011.09.137","article-title":"Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation","volume":"29","author":"Silveira","year":"2011","journal-title":"Vaccine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.vaccine.2014.01.040","article-title":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","volume":"32","author":"Ishikawa","year":"2014","journal-title":"Vaccine."},{"key":"B44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2017.02.005","article-title":"Prospects for a Zika virus vaccine","volume":"46","author":"Barouch","year":"2017","journal-title":"Immunity."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine."},{"key":"B46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1046\/j.1365-2249.1997.4311446.x","article-title":"Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEC)-infected macrophages","volume":"110","author":"Kreil","year":"1997","journal-title":"Clin Exp Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1128\/AM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microb."},{"key":"B48","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science."},{"key":"B49","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","article-title":"Vaccine protection against Zika virus from Brazil","volume":"536","author":"Larocca","year":"2016","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1099\/jmm.0.039180-0","article-title":"The current challenges for vaccine development","volume":"61","author":"Oyston","year":"2012","journal-title":"J Med Microb."},{"key":"B51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/82_2014_406","article-title":"Inactivated and adjuvanted influenza vaccines","volume":"386","author":"Giudice Del","year":"2015","journal-title":"Curr Topics Microb Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Thanh Le","year":"2020","journal-title":"Nat Rev Drug Disc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-042617-053142","article-title":"Immune response to dengue and Zika","volume":"36","author":"Elong Ngono","year":"2018","journal-title":"Ann Rev Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e02187","DOI":"10.1128\/JVI.02187-18","article-title":"Rational design of Zika virus subunit vaccine with enhanced efficacy","volume":"93","author":"Tai","year":"2019","journal-title":"J Virol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/jir.2017.0106","article-title":"T cell immunity to Zika and dengue viral infections","volume":"37","author":"Wen","year":"2017","journal-title":"J Interf Cytok Res."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T10:43:04Z","timestamp":1697971384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2021.632714"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632714","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"632714"}}